UK's MHRA Approves Mirdametinib To Treat Plexiform Neurofibromas
ReutersDec 11, 2025 2:34 PM
Dec 11 (Reuters) - UK's MHRA:
UK'S MHRA: MIRDAMETINIB APPROVED TO TREAT PLEXIFORM NEUROFIBROMAS IN CHILDREN, ADOLESCENTS, AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 - WEBSITE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
U.S. November CPI: How Will Inflation Fluctuations Transmit to US Stocks? Tariffs Are the Key!
TradingKey - It should be emphasised that tariff policy is the core driver sustaining the current high level of inflation,...Under the combined influence of tariffs and inflation, the U.S. stock market will probably follow a down-then-up trend in 2026.TradingKey
14 hours ago
Japan Central Bank Rate Hike To Three-Decade High Imminent, How Will The Market Go? Which Assets Most Affected?
As global monetary policy divergence enters a critical phase, the Bank of Japan (BoJ) is anticipated to raise its benchmark interest rate at the monetary policy meeting on December 19, 2025, by 25 basis points to 0.75% , marking its highest level in nearly 30 years.TradingKey
15 hours ago
Bitcoin Stocks 2025 Collective Plunge, Still Worth Investing in Future?
Bitcoin stocks involved in trading operations outperformed mining stocks and DAT-category stocks, thus warranting greater priority attention. If Bitcoin's future price trend indeed aligns with Grayscale's projection, Bitcoin stock prices are also expected to rebound and even reach new highs.TradingKey
Wed, Dec 17
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?TradingKey
Wed, Dec 10
Tradingkey
